Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Search

September 1998

Consolidation: Threat Or Opportunity

IS CONSOLIDATION GOOD OR BAD FOR OUR HEALTHCARE SYSTEM? I don’t know if any of us could accurately answer that question. For better or for worse, big corporations will continue to buy up the little guys. I do feel confident in predicting that ongoing consolidation will occur in all areas of healthcare. Among our readership, […]

To access this post, you must purchase The Dark Report.

Consolidation: Threat Or Opportunity Read More »

Bayer Acquires Chiron In Consolidation Move

CEO SUMMARY: As expected, consolidation within the diagnostics industry continues. This time it is Bayer, spending $1.1 billion to acquire Chiron’s diagnostics business. Once completed, Bayer will be the fourth-largest diagnostics company in the world. Laboratory customers of both firms will see many changes during the 18 months following the merger. ONCE AGAIN THE DIAGNOSTICS

To access this post, you must purchase The Dark Report.

Bayer Acquires Chiron In Consolidation Move Read More »

Chiron Is Biotech Firm, Respected For Innovation

CEO SUMMARY: Chiron is respected for its leadership in branched DNA and viral load technologies. The company had high expectations for its diagnostics group, particularly after its purchase of Ciba Corning. But rapid consolidation of the diagnostics industry changed Chiron’s opportunity to reach the first tier of diagnostic companies. Its experience demonstrates the far-reaching impact

To access this post, you must purchase The Dark Report.

Chiron Is Biotech Firm, Respected For Innovation Read More »

AutoCyte Moves One Step Closer To FDA Approval

CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs. AutoCyte’s product positioning will be very different than its competitors: NeoPath,

To access this post, you must purchase The Dark Report.

AutoCyte Moves One Step Closer To FDA Approval Read More »

Curse Of Consolidation Plagues Health Providers

WITHOUT QUESTION, today’s healthcare world is dominated by a single obvious trend: consolidation. The consequences of consolidation affect every segment of healthcare in the United States. The commercial laboratory industry had the dubious distinction of being the first major segment of healthcare to undergo consolidation. Laboratorians are still dealing with its lingering effects. Major cutbacks in

To access this post, you must purchase The Dark Report.

Curse Of Consolidation Plagues Health Providers Read More »

Pathologists Will Learn Income-Boosting Methods

CEO SUMMARY: Reimbursement for pathology services continues to decline. Despite this fact, savvy pathologists throughout the country are steadily increasing their take-home income. Their proven methods and secret strategies will be the theme of the Private Pathology Income Symposium. This year’s event will teach participating pathologists how to preserve and enhance their practice income. REIMBURSEMENT

To access this post, you must purchase The Dark Report.

Pathologists Will Learn Income-Boosting Methods Read More »

Unilab’s Bid To Buy Meris Will Shake Up California

CEO SUMMARY: More laboratory overcapacity may be removed from the California marketplace if Unilab purchases Meris Laboratories. Unilab’s offer to buy Meris must be cleared by the bankruptcy court and other bidders may surface during the coming weeks. These events are a reminder that financial pressure on the clinical laboratory industry continues to force change

To access this post, you must purchase The Dark Report.

Unilab’s Bid To Buy Meris Will Shake Up California Read More »

“September 28, 1998 Intelligence: Late Breaking Lab News”

Just days ago, Bayer AG announced one of the largest drug-discovery alliances ever created. Bayer will pay Millennium Pharmaceuticals, Inc. $465 million. In return, over a six-year period, Millennium will use genomics techniques to identify cures for various diseases. Millennium must deliver 225 drug “targets” or proteins that may be useful in designing drugs. MORE

To access this post, you must purchase The Dark Report.

“September 28, 1998 Intelligence: Late Breaking Lab News” Read More »

Pathologists, Clin Labs, Pharmacogenomics & PPMs

AT MY AGE, I AM LEARNING THAT PEOPLE TEND TO HOLD ONE OF TWO OPINIONS about me. It seems that I can frequently be considered a doddering old fool who is totally unhip (although I recall an even earlier generation calling it “unhep”). On the other hand, there are those who grant me great respect.

To access this post, you must purchase The Dark Report.

Pathologists, Clin Labs, Pharmacogenomics & PPMs Read More »

Pharmacogenomics Is The Coming Wave

CEO SUMMARY: It may be gloom and doom today in the clinical laboratory industry, but long term prospects for diagnostic testing are brightening. Increased understanding of human genetics drives new discoveries about how and why the same drug affects individuals differently. Biotech companies like Oncormed, Inc. are positioning themselves to apply this knowledge to diagnostic

To access this post, you must purchase The Dark Report.

Pharmacogenomics Is The Coming Wave Read More »

;